Clinical trial · Expanded Access
Individual Patient Compassionate Use of Mirdametinib
NCT05028166CI-TRIAL-00110859availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Histiocytic Neoplasm | Histiocytic and Dendritic Cell Neoplasm | ALIAS | 0.90 |
| Neurofibromatosis Type 1-Associated Plexiform Neurofibromas | — | UNRESOLVED | — |
| Other MAP-K Pathway Driven Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mirdametinib (MEK Inhibitor) | Drug | Mirdametinib | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 2 Years
Show eligibility criteria text
Inclusion Criteria: * Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. * Patient does not qualify to participate in an ongoing clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.